Tag: Psoriasis
New insights into psoriasis comorbidity
Long-term psoriasis treatment with bimekizumab results in maintained efficacy
Novel developments in topical psoriasis therapy
JAK inhibitors: A risk assessment
Intestinal microbe-preparation: Modest activity but safe for mild psoriasis
Potential biomarker discovered for treatment response to ustekinumab
TNF inhibitor for immune-mediated inflammatory disease doubles the risk of paradoxical psoriasis
Secukinumab also tolerable in paediatric psoriasis patients
High treatment success with ixekizumab in patients with psoriasis and diabetes
The Yin and Yang of opposing vectors: an explanation for side effects of biologics
Explaining arthropathy development through IL-4 and IL-13 blockade
DLQI scores underestimated during lockdowns?
TNF blockers likely beneficial for psoriatic patients with COVID-19
Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion
IL-36 gene expression in GPP lesions reduced by spesolimab
Inhibition of heat shock protein: A novel way to treat psoriasis?
Risankizumab superior to ustekinumab in skin histopathology scores
Tapering biologics: No alarming signs of increased anti-drug antibodies
Intermediate monocytes are possible predictors of response to secukinumab
Gut microbiota of psoriasis patients: less diverse and reduced functionality
Psoriasis associated with a higher cancer risk
Comorbidity and clinical features of psoriasis vary according to HLA-C*06:02 status
Psoriasis patients with cardiovascular comorbidity characterised by high systemic inflammation
HLA-C*06:02-positive patients on ustekinumab show higher drug survival in a real-world scenario
Protective factors identified against anti-drug antibody formation to adalimumab in psoriasis
Comparing routes of administration of methotrexate in psoriasis patients
TYK2 inhibitor deucravacitinib shows impressive long-term response in psoriasis
Tapinarof cream for psoriasis leads to high clearance rates and remittive effect
Existing and upcoming small molecules in psoriasis
Treating psoriasis during pregnancies
A patient-related approach to freedom of disease
Ixekizumab superior to secukinumab in real-world psoriasis study
Nail psoriasis: An important target to be treated
Grand debate: Is psoriasis a systemic or skin-only disease?
EADV 2021 Highlights Podcast
Real-world data on brodalumab affirms efficacy and fast onset of action
Bimekizumab in psoriasis: Up-and-coming
Biologic psoriasis treatment and COVID-19 risk: Contradictory results
Selective IL-23 blocker shows potential in psoriasis treatment
Promising results with nanobody treatment in psoriasis
Efficacious non-steroidal topical for psoriasis
How to manage cutaneous side effects of immunotherapy
Cannabinoids: a future role in dermatology?
Psoriasis therapy for children and pregnancies
Biologic psoriasis treatment to lower cardiovascular risk?
A new topical PDE-4 inhibitor effective in psoriasis
IL-17A and IL-17F blockade remarkably effective in psoriasis
Novel IL-23 blocker risankizumab highly effective and tolerable in psoriasis
Tape stripping – a painless way to distinguish AD and psoriasis?
Can gene expression help to pick the right biologic to treat psoriasis in cancer patients?
Lowest risk of infection after therapy with an IL-12/IL-23 blocker
Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib
Psoriasis onset determines sequence of symptoms
Selective IL-23 blocker shows remarkable efficacy in patients with psoriatic arthritis
IL-17A blocker effective in paediatric psoriasis patients
Small molecules: interesting novel treatment options in AD
Biologics: increasingly used in paediatric dermatology
Comorbidities more common in chronic urticaria, psoriasis, and AD
IL-17 blocker: effective and safe in patients with comorbidities
Reduced sleep quality in dermatoses influenced by itch and pain
ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker
Relationship psoriasis and NAFLD: new data on the hepato-dermal axis
Novel selective IL-23 blocker equally effective in patients with metabolic syndrome
Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints
Certolizumab pegol efficacious for head and neck psoriasis
No hint of teratogenicity through ixekizumab
Novel treatment options for many dermatologic indications
Choosing the right biologic in psoriasis
Novel selective IL-23 blocker highly effective over 2 years
Registries – an important research tool in biologics
Favourable safety profile of long-term use of ixekizumab
Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies
Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity
Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients
Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis?
Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis
ABP501 biosimilar for adalimumab: What you need to know
Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies
Certolizumab: Long-term safety and efficacy results for psoriasis-related nail disease
Reduction in coronary artery disease in psoriasis patients treated with biologic therapies, possible implications for atopic dermatitis
Atopic dermatitis and psoriasis: on a spectrum?
Small molecules, apremilast, and TYK2
IBD risk of treatment with IL-17 antagonists
Secukinumab maintains improvements in psoriasis through 5 years of treatment
Dual IL-17A and IL-17F blocker leads to unprecedented response rates in psoriasis
Serlopitant reduces pruritus associated with psoriasis
Psoriasis and Biologics: The Beat Goes On
Improvement in impact of genital psoriasis on sexual activity with use of ixekizumab
Intralesional cryosurgery and itching in psoriasis
